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Sphingosine 1-phosphate is a novel inhibitor of T-cell proliferation
Yixin Jin, Eirunn Knudsen, Ling Wang, Yenan Bryceson, Bassam Damaj, Sandra Gessani, and AzzamA. Maghazachi
Sphingosine1-phosphate(S1P)isapleio-
tropic lysosphingophospholipid stored
and secreted by platelets. Using reverse
transcription–polymerase chain reaction
and ﬂow cytometric analyses, we deter-
mined the expression of S1P receptors
(S1P1, S1P3, S1P4, and S1P5) in peripheral
blood T cells. T cells were induced to
proliferate in the presence of phorbol
12-myristate 13-acetate (PMA) plus iono-
mycin, anti-CD3 plus anti-CD28, and allo-
geneicimmatureormaturedendriticcells.
This activity was inhibited by the addition
of S1P. Enhanced T-cell proliferation was
observed when these cells were stimu-
lated with the same stimuli, but were
incubated in serum-free media (SFM).Ad-
dition of S1Pto SFM inhibited the stimula-
tion of T cells induced by T-cell stimuli,
suggestingthatS1Pisanimportantinhibi-
tory molecule present in the serum. T-cell
proliferation was also inhibited by the
addition of dihydrosphingosine 1-phos-
phate (DHS1P), sphingosine, and cer-
amide;however,thelatter2sphingolipids
required higher concentrations than S1P.
Pretreatment of T cells with pertussis
toxin (PTX) blocked the inhibitory effect
of S1P on activation with PMA plus iono-
mycin, but not on activation with anti-CD3
plus anti-CD28. This is corroborated with
the down-regulation of S1P1 in T cells
stimulated with anti-CD3 plus anti-CD28.
Similarly, PTX did not affect the inhibitory
effect of S1P on T-cell proliferation when
dendritic cells were used as stimuli. Fur-
ther, S1P or DHS1P but not ceramide or
sphingosine enhanced rather than de-
creased secretion of interleukin 2 and
interferon  by T cells stimulated with
anti-CD3 plus anti-CD28. These results
show differential effects of S1P on poly-
clonal T-cell proliferation and cytokine
secretion. (Blood. 2003;101:4909-4915)
© 2003 by TheAmerican Society of Hematology
Introduction
Sphingosine 1-phosphate (S1P), a lysosphingophospholipid, is
generated by the conversion of sphingomyline into ceramide by
sphingomylinase, ceramide into sphingosine by ceramidase, and
sphingosine into S1Pby sphingosine kinase.1 S1Pacts exogenously
by binding 7 transmembrane-spanning domain receptors that bind
heterotrimeric G proteins.2,3 S1P1 couples to the pertussis toxin (PTX)–
sensitive Gi and Go, whereas S1P2, S1P3, S1P4, and S1P5 bind to the
PTX-sensitive as well as the PTX-insensitive Gq,G 12,o rG 13.4-6
S1P is secreted by platelets, binds albumin, and represents a
large percentage of bovine and human serum.7,8 The total S1P
contents in human plasma and serum reach micromolar concen-
trations.7 Although platelets are considered to be the major
source of S1P, other cell types such as erythrocytes, neutrophils,
and mononuclear cells also secrete S1P.8 Goetzl et al9,10
described the presence of S1P and lysophosphatidic acid (LPA)
receptors in T cells, with an emphasis on the expression of LPA
receptors such as LPA1 and LPA2.L P A 2 seems to play a major role in
LPA-inhibition of apoptosis.9,10 Also, LPA has dual effects on the
proliferation of various cell types. For example, it induces the prolifera-
tion of NIH 3T3 ﬁbroblasts, whereas it inhibits the proliferation of cells
of myeloid and lymphoid origin, such as YAC-1 lymphoma, EL4
lymphoma, or SP2 myeloma, among others.11 On the other hand, S1P
either stimulates DNA synthesis in 3T3 ﬁbroblasts12 or inhibits DNA
synthesis in primary hepatic myoﬁbroblasts.13
Although the effect of LPA has been described in T cells, where it
blocks secretion of interleukin 2 (IL-2),9,10 little is known about the
effect of S1P on T cells. Recently, Idzko and coworkers reported that
S1P receptors are expressed on the surface of immature and mature
dendritic cells (DCs), associated with favoring the polarization of Th2
cells by mature DCs generated in the presence of S1P.14 Also, recent
results have shown that S1P and its derivatives induce lymphopenia in
animals, associated with increased sequestration of lymphocytes in the
lymph nodes and thoracic ducts.15 Here, we have examined the
immunoregulatory action of S1P, with an emphasis on T-cell prolifera-
tion and cytokine secretion.
Materials and methods
Culture medium
Culture medium (CM) consisted of RPMI 1640 supplemented with 10% fetal
calf serum, 10 U/mL penicillin, 100 g/mL streptomycin, 1 mM L-glutamine,
and 1% nonessential amino acids (Gibco BRL Life Technologies, Breda, the
Netherlands) and 5 105 M 2-mercaptoethanol (Sigma-Aldrich, Oslo, Nor-
way). Serum-free medium (AIMV) was purchased from Gibco BRL.
Reagents and antibodies
S1P, sphingosine (D-erythro-sphingosine), ceramide, phorbol 12-myristate
13-acetatae (PMA), ionomycin, mitomycin C, PTX, and lipopolysaccharide
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4909 BLOOD, 15 JUNE 2003 VOLUME 101, NUMBER 12(LPS) were purchased from Sigma-Aldrich. Dihydrosphingosine 1-phos-
phate (DHS1P) was purchased from Avanti Polar Lipid (Alabaster, AL).
Recombinant human IL-4 was from Nordic Biosite (Propellervagen,
Sweden), and recombinant human granulocyte-macrophage colony-
stimulating factor (rhGM-CSF) was from Gibco BRL.Antibodies to human
CD3, or CD28, and ﬂuorescein isothiocyanate (FITC)–conjugated antibod-
ies to human CD80, CD83, CD86, or mouse IgG1 were purchased from
Becton Dickinson Pharmingen (Laborel AS, Oslo, Norway). Rabbit poly-
clonal antibodies to the carboxy-terminal of S1P1, S1P4, and S1P5,
monoclonal antibodies to the amino-terminal of S1P2 and S1P3, and
peptides speciﬁc for anti-S1P1 or anti-S1P5 were purchased from Sigma-
Aldrich. Monoclonal anti-S1P3 was purchased from Exalpha Biologicals
(Boston, MA).
Semiquantitative RT-PCR
Peripheral blood T cells were isolated by depleting other leukocyte
populations using a pan T-cell isolation kit (Miltenyi Biotech,
Bergisch Gladbach, Germany). These cells were more than 98%
CD3 as determined by ﬂow cytometric analysis. Jurkat, PEER,
NK92, 221, U937, and RPMI 8866 (designated RPMI in Figure 1)
cell lines were cultured in Iscove media supplemented with 10%
fetal bovine serum (FBS). Preparation of RNAand the sequences of
primer pairs for S1P1, S1P3, S1P4, and S1P5 have been recently
described.16 The primers for glyceraldehyde-3-phosphate dehydroge-
nase (G3PDH) were: 5-GGCATGGACTGTGGTCATGAG-3 and
5-TGCACCACCAACTGCTTAGC-3. Reverse transcription–poly-
merase chain reaction (RT-PCR) products were prepared as described.16
Immunoﬂuorescence analysis
Intracellular labeling of S1Preceptors was done using polyclonal antibodies
to the carboxy-terminal of S1P1, S1P4, and S1P5 or monoclonal antibodies
to the amino-terminal of S1P2 and S1P3. T cells (1  105) were seeded in
v-bottom 96-well plates and washed once with 150 L washing buffer
(phosphate-buffered saline [PBS] plus Ca and Mg, 0.1% bovine
serum albumin [BSA], and 10 mM sodium azide), and once with PBS
alone. They were incubated with 100 L ﬁxative (4% paraformaldehyde in
PBS, pH 7.4), and incubated for 15 minutes at room temperature. The cells
were washed once with PBS and once with permeabilization buffer (0.1%
saponin in washing buffer). They were resuspended in 100 L permeabili-
zation buffer, and incubated for 15 minutes at room temperature.After this,
the cells were spun down and resuspended in 10 Lpermeabilization buffer
and appropriate dilutions of anti-S1P receptor antibodies (2 g/10 L  1:
5 dilution, 1 g/10 L  1:10 dilution, etc). Several dilutions of the
antibodies (1:5-1:500) were used. Similar concentrations of rabbit IgG or
mouse IgG (Sigma-Aldrich) were used as controls. The cells were
incubated with the antibodies for 1 hour at 4°C. They were washed twice
with permeabilization buffer, resuspended in 1:50 dilution of the secondary
antibody, FITC-conjugated F(ab)2 sheep antimouse (Sigma-Aldrich) or
FITC-conjugated F(ab)2 donkey antirabbit (Jackson Immunoresearch
Laboratories, West Grove, PA), and incubated for 30 minutes at 4°C. They
were washed twice with permeabilization buffer and resuspended in 400 L
washing buffer before examining in the ﬂow cytometer (FACSCalibur,
Becton Dickinson Biosciences, San Jose, CA). For the binding of antibod-
ies to peptides, 50 molecules of the peptide (S1P1 or S1P5) were incubated
with one molecule of the antibody (anti-S1P1 or anti-S1P5) for 20 minutes at
37°C, before examining these antibodies for their binding to T cells.
Pretreatment with PTX
T cells (1  106/mL) were either left intact or were treated with 100 ng/mL
activated PTX overnight at 37°C. The cells were then washed 3 times with
culture medium.
Preparation of DCs
Peripheral blood cells were collected from blood bank healthy volunteers
(Ullevål Hospital, Oslo, Norway) and centrifuged over lymphoprep gradi-
ents (Nycomed, Oslo, Norway). Mononuclear cells were isolated and
incubated (1  107/mL, total volume 10 mL) in 100-mm Petri dishes at
37°C for 2 hours, and the adherent cells were collected. These cells
contained about 90% CD14, about 10% CD19 B cells, and no CD3 T
cells as determined by ﬂow cytometric analysis. CD14 cells were cultured
at 5  106/mL with 6 ng/mL IL-4 and 25 ng/mL rhGM-CSF for 5 days at
37°C to generate immature (i) DCs. In the middle of the culture period (2.5
days later), the cells were supplemented with 1 mL fresh media containing
IL-4 and GM-CSF. The phenotypes of both iDCs and mature (m) DCs were
routinely checked by ﬂow cytometric analysis. The iDCs showed low
expression of CD80 and CD86, but not CD83 or CD14, whereas mDC
highly expressed CD80, CD86, and CD83, but not CD14. In addition, the
morphology of both cell types was routinely examined by cytospin analysis
after each preparation, to ascertain that DCs are generated.
Proliferation assay
The 96-well plates were coated overnight at 4°C with 1 g/mL
(100 ng/100 L) anti-CD3 and washed 3 times with PBS. T cells
(1  105/100 L) and 100 ng/100 L anti-CD28 were added to
each well. For activation with PMA plus ionomycin, 10 ng/mL
(1 ng/100 L) of each was added to the wells in the presence of
1  105 T cells/well. Three days later, 1 Ci/well (0.037 MBq)
[3H]thymidine (Amersham Pharmacia Biotech, Oslo, Norway) was
added to each well as previously described.17 Six hours later, the
cells were harvested using a cell harvester (Skatron Instrument,
Lier, Norway) on glass-ﬁber ﬁlters, and then counted in a beta
counter. Each experiment was done 4 to 6 times; however, due to
Figure 1. Expression of S1P receptors in peripheral blood T cells. (A) mRNA for
peripheral bloodTcells and forT-cell lines (Jurkat and PEER), an NK-cell line (NK92),
B-cell lines (RPMI and .221), and a monocytic cell line (U937) is shown. Shown is
RT-PCR analysis of mRNA for S1P1, S1P3, S1P4, and S1P5, as well as the
housekeeping gene for glyceraldehyde-3-phosphate dehydrogenase (G3PDH).
(B) Flow cytometric analysis of the expression of S1P receptors in peripheral blood T
cells is shown. Background controls in the presence of rabbit IgG (for S1P1, S1P4,
and S1P5) or mouse IgG (for S1P2 and S1P3) and FITC-conjugated secondary
antibodies are shown in black. In the panel designated S1P2/S1P3, white and black
histograms represent the binding of monoclonal anti-S1P2 and anti-S1P3, respec-
tively. Numbers indicate the percentage of positive cells. (C)Anti-S1P1 and anti-S1P5
were either left intact or were incubated with S1P1 or S1P5 peptide prior to binding the
antibodies with T cells. Control is the binding of rabbit IgG plus secondary antibody.
4910 JIN et al BLOOD, 15 JUNE 2003 VOLUME 101, NUMBER 12the variations in the proliferative response among individuals, only
a single representative experiment is shown.All experiments show
a similar response pattern. For DC-induced T-cell proliferation,
iDCs were incubated with 1 g/mL mitomycin C for 45 minutes at
37°C, and then washed 4 times to remove any residual mitomycin
C. Mitomycin C was used to block DNA synthesis by these DCs.
The iDCs (1  105) were incubated with T cells (5  105)i n
96-well plates for 72 hours. These are considered iDC plus T cells.
In other cultures, 1 g/mLLPS was added to induce the generation
of mDC. These are considered mDC plus T cells.
Measurement of IL-2 and IFN- secretion
The 24-well plates were coated with 1 g/mL anti-CD3 overnight at 4°C.
After washing the plates, T cells (1  106/mL) and 1 g/mL anti-CD28
were added, in the presence or absence of S1P, DHS1P, ceramide, or
sphingosine, incubated for 24 hours at 37°C, and the supernatants were
collected from these cultures. The concentrations of IL-2 and interferon 
(IFN-) were measured by enzyme-linked immunosorbent assay (ELISA)
using Quantikine ELISA kits (R & D Systems, Abingdon, United King-
dom). Each experiment was done 4 times; however, only representative
experiments are shown due to the variation among individuals.
Statistical analysis
Signiﬁcant values were determined by using the 2-tailed Student t test.
Results
Expression of S1P receptors in T cells
We recently reported that human natural killer (NK) cells express S1P1,
S1P4, and S1P5, but not S1P2 or S1P3.16 Here, we examined the
expression of these receptors in peripheral blood T cells using RT-PCR.
The results show that peripheral blood T cells and the / T-cell line
(PEER) expressed S1P1, S1P3, S1P4, and S1P5. However, the CD4cell
lineJurkatexpressedonlyS1P1andS1P3,butnotS1P4andS1P5(Figure
1A). No T cells or T-cell lines expressed mRNA for S1P2 (data not
shown). For controls, we used NK (NK92), B (RPMI8866 and.221),
and monocytic (U937) cell lines. A noticeable observation is the
expression of mRNAfor S1P5 in T cells and PEER cell line only.Also,
S1P4hasrelativelyhightranscriptlevelsintheseTcellswhencompared
with other cells. No signal was observed in the absence of reverse
transcriptase. Previous work showed weak expression of S1P3 but not
S1P1 in human CD4 T cells,9,10 whereas S1P4 was expressed in
lymphoid tissues.18 Hence, the expression of S1P receptors described
here is the ﬁrst comprehensive effort to show the presence of S1P
receptors in humanTcells.
In addition, the expression of S1P receptors by ﬂow cytometric
analysiswasexamined.ResultsinFigure1Bshowthebindingof1:10to
1:50 dilutions of the antibodies. However, polyclonal anti-S1P1 and
anti-S1P4 showed strong binding at the 1:200 dilution, whereas poly-
clonal anti-S1P5 and monoclonal anti-S1P3 bind at 1:10 to 1:50
dilutions. Between 83% and 98%, 1% and 15%, 30% and 50%, and 5%
and 25% of T cells expressed S1P1, S1P3, S1P4, and S1P5, respectively.
Similar to RT-PCR, T cells did not express S1P2. In fact, the binding of
antibody to S1P2 was weaker than the binding of mouse IgG control.
Although other donor T cells expressed between 10% and 15% S1P3,T
cells from the donor shown in Figure 1 expressed only 1% of this
receptor. However, when we used monoclonal anti-S1P2 rather than
mouse IgG as a background control for monoclonal anti-S1P3,w e
observedthatabout10%ofTcellsexpressedS1P3(S1P2/S1P3inFigure
1B). Although anti-S1P3 is directed to the amino-terminal of the
receptor, this antibody binds better to T cells when these cells are
permeabilized. This could be due to conformational changes that may
occur in the receptor on permeabilization, which allow the exposure of
those epitopes that bind the antibody. Collectively, these results repre-
sent the ﬁrst demonstration of a successful use of anti-S1Pantibodies in
the ﬂow cytometric analysis, in any cell type. The only other report that
showed the expression of S1P4 by ﬂow cytometry used c-myc epitope-
tagged S1P4and anti–c-myc antibody.19
The level of mRNAfor S1P1 and S1P5 is almost similar (Figure
1A). However, only 5% to 25% of T cells expressed S1P5, whereas
more than 90% of the cells expressed S1P1 (Figure 1B). This could
be due to a different mRNA stability between S1P1 and S1P5 as
well as to differences in their translation efﬁcacy. To determine the
speciﬁcity of anti-S1P1 and anti-S1P5, we incubated these antibod-
ies with speciﬁc as well as with nonspeciﬁc peptides prior to their
examination by ﬂow cytometry. Results in Figure 1C show that the
binding of anti-S1P1 to T cells was completely blocked on its
preincubation with S1P1 but not with S1P5 peptide. Reciprocally,
the binding of anti-S1P5 to T cells was blocked on its preincubation
with S1P5 but not with S1P1 peptide.
Effect of S1P on the proliferation of polyclonal T cells
To examine the function of S1P receptors in T cells, we used the
combination of anti-CD3 plus anti-CD28, or PMAplus ionomycin.
Anti-CD3 or PMA alone induced low proliferative responses,
whereas ionomycin, anti-CD28, or control antibodies did not (data
not shown).At 10 ng/mL, PMAplus ionomycin induced signiﬁcant
T-cell proliferation (P 	 .0006 compared with the control). Addi-
tion of 1 to 10 M S1P alone did not affect T-cell proliferation;
however, addition of 10 M S1P inhibited T-cell proliferation
triggered by PMAplus ionomycin (P 	 .01; Figure 2A). Similarly,
Figure 2. Effect of S1P on polyclonal T-cell proliferation. T cells were incubated
with 10 ng/mLPMAplus ionomycin (IONO), or 1 g/mLplated anti-CD3 plus 1 g/mL
anti-CD28, in the absence or the presence of 0.1 to 10 M S1P for 3 days at 37°C.At
this time, 1 Ci (0.037 MBq) [3H]thymidine ([3H]Tdr) was added to each well, and the
cultures were incubated for an additional 6 hours before harvesting (A). The same
experiment was conducted in serum-free media (SFM) (B).Tcells (1  106/mL) were
treated with 100 ng/mLPTX for 18 hours. These cells were washed 3 times, and then
incubated with the various stimuli in the absence or presence of different concentra-
tions of S1P (C). cpm indicates counts per minute.
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tion (P 	 .0002). This activity was inhibited by the addition of 0.1,
1, or 10 M S1P (P 	 .002). A higher T-cell proliferation was
observed when the experiments were done in serum-free media
(SFM). There was 2- to 3-fold enhancement of T-cell proliferation
on activation with PMA plus ionomycin, and about 4- to 5-fold
increase on activation with anti-CD3 plus anti-CD28 as compared
with T-cell proliferation in media with serum (Figure 2B versus
2A), indicating that there are inhibitory factors present in the media
supplemented with serum that regulate polyclonal T-cell prolifera-
tion.This was a consistent ﬁnding and was observed in more than 5
experiments conducted.
PMA plus ionomycin induced T-cell proliferation in SFM
(P	.0001), and this proliferation was inhibited by the addition of 0.1,
1, or 10 M S1P (P	.05, 	.05, or 	.01, respectively). Anti-CD3
plus anti-CD28 also enhanced T-cell proliferation in SFM (P	.0001),
and this response was inhibited by the addition of 1 or 10 M S1P
(P	.01). There was T-cell proliferation even in the presence of high
concentrations of S1P (Figure 2B), suggesting that although S1P is an
important inhibitory molecule present in the serum, this molecule may
not be the sole inhibitor. In fact, 0.1 M S1P inhibited T-cell prolifera-
tion only in the presence of serum when anti-CD3 and anti-CD28 were
used as stimuli, suggesting that S1Pmay synergize with other inhibitory
molecules present in the serum. The approach of adding S1P to SFM is
similar to the approach of Yanai et al,20 who observed that primitive
hematopoietic THS119 did not invade the stromal cell layer in the
absence of FBS. However, these cells restored their ability to invade on
the inclusion of either FBS, S1P, or LPAin the media.20 Last, we did not
observe differences in S1P receptor expression in T cells cultured in
SFM, except for a low expression of S1P5 (data not shown), suggesting
that the inhibition is related to the addition of the ligand.
Because receptors for S1P are coupled to PTX-sensitive as well
as PTX-insensitive G proteins,1-6,16 we performed the experiments
with T cells pretreated with PTX. Our results show that there was
an increase in PTX-pretreated T-cell proliferation on stimulation
with PMAplus ionomycin when compared withT-cell proliferation
in the presence of the same molecules but without PTX treatment
(Figure 2C versus 2A), suggesting that the inhibitory molecule in
the serum functions through PTX-sensitive G proteins and that on
blocking these G proteins with PTX, a higher proliferation of T
cells is revealed. Hence, PTX-pretreated T cells signiﬁcantly
proliferated on stimulation with PMA plus ionomycin (P 	 .0001;
Figure 2C). Addition of S1P failed to inhibit this proliferation,
indicating that S1P acts through PTX-sensitive G protein–coupled
receptors, on stimulating T cells with PMA plus ionomycin. In
contrast, there was no difference in T-cell proliferation after
activation with anti-CD3 plus anti-CD28 on pretreatment with PTX
(Figure 2C versus 2A). These antibodies triggered signiﬁcant
proliferation of T cells pretreated with PTX (P 	 .001), and
addition of 0.1 to 10 M S1Pinhibited this proliferation (P 	 .001;
Figure 2C).
In addition to S1P, 0.1, 1, and 10 M concentrations of DHS1P
inhibited T-cell proliferation induced by anti-CD3 plus anti-CD28
(P	.05, 	.01 and 	.05, respectively; Figure 3). Because S1P may
enter the cells and may be converted into sphingosine by sphingosine
1-phosphate phosphatase and to ceramide by ceramidase, which have
antiproliferative or apoptotic activities in various cell types,21,22 we
examined the effect of these metabolites on T-cell proliferation. Only 1
or 10 M ceramide (P	.02, and 	.005, respectively), and 10 M
sphingosine (P	.02) were inhibitory forT-cell proliferation (Figure 3).
Hence, although ceramide and sphingosine are inhibitory, they required
higher concentrations than S1P or DHS1P. It is difﬁcult to attribute the
inhibitory effect of 0.1 M S1P to its conversion to 1 and 10 M
ceramide or 10 M sphingosine, concentrations that are inhibitory for
T-cell proliferation (Figure 3).
Regulation of S1P receptor expression by different
T-cell stimuli
The differential effect of PTX on S1P activity in the presence of
different stimuli suggests that perhaps there may be differential
regulation of S1P receptor expression in T cells incubated with
various stimuli. Consequently, we examined the expression of
receptors for S1P after stimulation with PMA plus ionomycin, or
anti-CD3 plus anti-CD28. Before stimulation, between 83% and
98% (mean 
 SEM is 91 
 3.1, n  4) of T cells expressed S1P1.
Stimulation with PMA plus ionomycin down-regulated to some
extent the expression of S1P1 (Figure 4 shows a representative
experiment, mean 
 SEM is 73 
 9, n  3). However, a persistent
down-regulation of this receptor was observed after stimulation
with anti-CD3 plus anti-CD28; in the experiment shown in Figure
Figure 3. Sphingolipids inhibit T-cell proliferation with different dose re-
sponses. T cells were either left intact (, left column) or were stimulated with
1 g/mL plated anti-CD3 plus 1 g/mL anti-CD28 (f), for 3 days in the presence or
absence of different concentrations of S1P, DHS1P, ceramide (CER), or sphingosine
(SPH), in media supplemented with 10% serum. The incorporation of [3H]thymidine
was done as in Figure 2. P values comparing T-cell proliferation in the presence of
sphingolipids to the proliferation in their absence are placed on top of each column.
Data are representative of 3 experiments performed. Error bars indicate means 

SD; NS, not signiﬁcant.
Figure 4. Differential regulation of S1P receptor expression on activation.
T cells were either left intact (nonactivated) or were activated with PMA plus
ionomycin or anti-CD3 plus anti-CD28 for 3 days. These cells were then labeled with
antibodies to S1P1, S1P2, S1P3, S1P4,o rS 1 P 5. Background controls in the presence
of rabbit IgG (for S1P1, S1P4, and S1P5) or mouse IgG (for S1P2 and S1P3) and
FITC-conjugated secondary antibodies are shown in black. Numbers indicate the
percentage of positive cells in one experiment. In 3 to 4 experiments performed, the
percentage of positive cells for S1P1, S1P2, S1P3, S1P4, and S1P5 ranges between
83% and 98%, less than 0.1%, 1% and 15%, 25% and 50%, and 5% and 25% for
nonactivated cells; 52% to 83%, less than 0.1%, 15% and 40%, 20% and 30%, and
23% and 41% for PMA plus ionomycin-treated cells; and 5% and 70%, less than 0.1%,
15% and 30%, 20% and 25%, and 12% and 26% for anti-CD3 plus anti-CD28 activated
cells, respectively. White histograms represent the binding of the speciﬁc antibodies.
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stimulation with these antibodies. In other experiments, anti-CD3
plus anti-CD28 reduced the expression of S1P1 with varying
degrees depending on the donor (mean 
 SEM is 38 
 18, n  3).
No effect on the expression of S1P2 was observed after stimulation.
On the other hand, stimulation with PMA plus ionomycin or
anti-CD3 plus anti-CD28 up-regulated the expression of S1P3 on
about 15% to 40% and 15% to 30% of the cells, respectively
(Figure 4). Also, both stimuli up-regulated the expression of S1P5,
but down-regulated the expression of S1P4 (Figure 4).
Effect of S1P on DC-induced T-cell proliferation
Because antigens are presented to T cells by professional antigen-
presenting cells, such as DCs, we examined the ability of both iDCs
and mDCs to affect allogeneic T-cell proliferation. Incubation of
iDCs or mDCs with T cells induced potent T-cell proliferation
(P 	 .0001 compared with T cells incubated with medium only;
Figure 5A).To control for the effect of LPS, or the ability of DCs to
proliferate, we examined whether T cells or iDCs proliferate in the
presence of LPS. The results showed that none of these cells
proliferated in the presence of LPS (Figure 5A). Addition of 0.01,
0.1, or 1 M S1P inhibited the induction of T-cell proliferation
induced by either iDCs or mDCs (P 	 .01-.001 depending on the
S1P dose used, as compared with cells proliferated in the absence
of the phospholipid). There was about a 2- to 3-fold increase in
T-cell proliferation on performing these experiments in SFM
(Figure 5B versus 5A), again suggesting that there must be
inhibitorymoleculespresentintheserumthatblockT-cellprolifera-
tion. Addition of 0.1 or 1 M S1P signiﬁcantly inhibited the effect
of iDCs on T cells in SFM (P 	 .05). Also, addition of 0.01 to 1
M S1P reduced T-cell proliferation when incubated with alloge-
neic mDCs in SFM (P 	 .03).These results suggest that S1Pis one
of the molecules present in the serum, which inhibits DC triggering
of T-cell activation. PTX was also used to examine the signals
activated on the interaction between DCs and T cells. PTX-
pretreated cells proliferated similarly to PTX-untreated T cells
(Figure 5C versus 5A).Also similar to PTX-untreated T cells, 0.01
to 1 M S1P inhibited the proliferation of PTX-pretreated T cells
induced by either iDCs (P 	 .005) or mDCs (P 	 .01), suggesting
that PTX-insensitive G proteins are involved in DC/T-cell
interaction.
Effect of S1P on the secretion of IL-2 and IFN- by activated
T cells
To examine other immunoregulatory effects of S1P, we collected
supernatants from T cells stimulated with anti-CD3 plus anti-
CD28. The levels of IL-2 or IFN- in these supernatants were
measured by ELISA. T cells stimulated with PMA plus ionomycin
did not secrete signiﬁcant amounts of these cytokines (data not
shown). However, T cells incubated with anti-CD3 plus anti-CD28
secreted signiﬁcant amounts of IL-2 (P 	 .001 as compared with T
cells incubated with medium only; Figure 6). Surprisingly, 1 or 10
M S1P enhanced IL-2 secretion by T cells stimulated with
anti-CD3 plus anti-CD28 (P 	 .005 as compared with cells
activated with the antibodies but not with S1P). This activity was
mimicked by DHS1P, which also stimulates the secretion of IL-2
when used at 1 or 10 M( P 	 .005). In contrast, 10 M of either
ceramide or sphingosine inhibited this secretion (P 	 .01 and
	 .001, respectively, when compared with IL-2 secretion in the
presence of anti-CD3 plus anti-CD28 only). Signiﬁcant IFN- was
also secreted by T cells stimulated with anti-CD3 plus anti-CD28
(P 	 .001 compared with T cells not stimulated with the antibod-
ies). Similar to the results of IL-2 secretion, 1 or 10 M
concentration of S1P increased the level of IFN- secreted by T
cells (P 	 .01 compared with cells stimulated with the antibodies,
but in the absence of S1P). This enhancement occurred only on
activation; that is, addition of S1Pto T cells in the absence of T cell
stimuli did not induce the secretion of IL-2 or IFN- (data not
shown). One or 10 M DHS1P also stimulated IFN- secretion
(P 	 .01). Similar to their effects on IL-2 secretion, 10 M
Figure 5. Effect of S1P on T-cell proliferation induced by DCs. Allogeneic iDCs
were incubated with T cells for 3 days in media supplemented with serum in the
absenceorpresenceof1 g/mLLPS(togeneratemDCs).Thesecultureswereeither
left intact or were incubated with 0.01 to 1 M S1P for 3 days. At this time, 1 Ci
(0.037 MBq) [3H]thymidine was added, and the cultures were incubated for an
additional 6 hours before harvesting (A). The same experiment was conducted in
SFM (B). T cells were pretreated with PTX and then incubated with DCs in the
presence of serum (C). Control samples include T cells alone, iDCs alone, iDCs
incubated with 1 g/mLLPS, and T cells incubated with 1 g/mLLPS in the presence
or absence of S1P. Error bars indicate means 
 SD.
Figure 6. S1P enhances IL-2 and IFN- secretion by T cells stimulated with
anti-CD3 plus anti-CD28. T cells (1  106/mL) were stimulated with 1 g/mL
anti-CD3 plus anti-CD28 for 24 hours in the absence or presence of 1 or 10 M S1P,
DHS1P, ceramide (CER), or sphingosine (SPH). Supernatants were collected from
these cultures. IL-2 and IFN- levels were measured by Quantikine ELISA. Error bars
indicate means 
 SD.
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cells (P 	 .05 and 	 .0001, respectively).
Discussion
S1P is secreted by platelets and constitutes a high proportion of
serum and plasma.7,8 It is also secreted by various cell types on
stimulation of protein kinase C.23 However, its immunoregulatory
role is not extensively studied. Here, we show for the ﬁrst time the
expression of S1P receptors in peripheral blood T cells by
immunoﬂuorescence analysis. We combined this technique with
the expression of the receptor at the mRNA level by RT-PCR.
Because S1P stimulates the chemotaxis of human NK cells,16 and
because it is antiapoptotic and stimulates the proliferation of
various cell types,1,12,22 we were surprised to observe that it inhibits
the proliferation of polyclonal T cells. Addition of this phospho-
lipid inhibits T-cell proliferation induced by several stimuli,
including PMA plus ionomycin, anti-CD3 plus anti-CD28, and
iDCs and mDCs. It was previously reported that S1P acts either
extracellularly,24 intracellularly,25 or both.26 Our results favor
receptor-mediated activity of S1P for the following reasons.
(1) DHS1P, which acts on S1P plasma membrane receptors, and
does not have intracellular activity, mimicked the inhibitory effect
of S1P on T cell proliferation. (2) Sphingosine and ceramide, the
metabolites that can be generated from the conversion of S1P, also
inhibit T-cell proliferation. However, these sphingolipids inhibit
T-cell proliferation with higher concentrations than did S1P or
DHS1P (Figure 3). (3) The inhibitory effect of S1P on T-cell
proliferation is observed only after stimulating T cells with
anti-CD3 plus anti-CD28, iDCs or mDCs, which engage T-cell
receptors, suggesting that S1P action is related to the expression of
receptors for S1P after activation with these stimuli. (4) PTX
blocked the inhibitory activity of S1P when PMA plus ionomycin
were used as stimuli. (5) S1P as well as DHS1P enhanced the
secretion of IL-2 and IFN- by T cells stimulated with anti-CD3
plus anti-CD28, an activity that cannot be attributed to sphingosine
and ceramide. In fact, both ceramide and sphingosine when used at
10 M concentration markedly inhibited the secretion of
both cytokines.
PTX, which blocks Gi, reversed the inhibitory effect of S1P
after stimulation with PMA plus ionomycin, but did not affect it
when anti-CD3 and anti-CD28 were used. This activity resembles
to some extent the effect of LPAin ﬁbroblasts, where LPAenhances
mitogen-activated protein kinase activation via PTX-sensitive G
proteins, but activates p125FAK through PTX-insensitive G pro-
teins.27 Here, we observed that triggering T-cell receptors (TCRs)
with anti-CD3 plus anti-CD28 down-regulated the expression of
S1P1, which couples to PTX-sensitive G proteins, and up-regulated
the expression of S1P3, which is coupled to PTX-sensitive as well
as PTX-insensitive G proteins.4,5 Although stimulation with PMA
plus ionomycin also down-regulated the expression of S1P1, in all
the experiments performed, a lower percentage of T cells express-
ing this receptor was observed after stimulation with anti-CD3 plus
anti-CD28 than after stimulation with PMAplus ionomycin. These
results may explain how PTX reversed the inhibitory effect of S1P
on activating T cells with PMA plus ionomycin but not on
activation with anti-CD3 plus anti-CD28. PTX also did not affect
S1P inhibitory action on stimulating T cells with DCs. Unfortu-
nately, we could not completely separate T cells from DCs to
examine the expression of receptors for S1P in T cells after
stimulation with DC. It is plausible that stimulation with DC may
up- or down-regulate the expression of S1P receptors in T cells.
Last, PMA plus ionomycin or anti-CD3 plus anti-CD28 down-
regulated the expression of S1P4 and up-regulated the expression of
S1P5 in T cells 3 days after stimulation.
Surprisingly, we observed that S1P enhances IL-2 and IFN-
secretion on stimulation with anti-CD3 plus anti-CD28. The reason
for increased cytokine secretion is not known, but it may be related
to the up-regulation of S1P3 and S1P5 on T cells stimulated with
anti-CD3 plus anti-CD28, although this has not been tested. These
results indicate that although S1P inhibits the proliferation of T
cells, it induces their terminal differentiation exempliﬁed by
cytokine secretion. The results are reminiscent of the effect of LPA
on IL-2 secretion by phytohemagglutinin (PHA)–activated T cells,
where LPA enhances rather than reduces the secretion of IL-2 in
activated T cells.28
Recent studies suggest that a direct interaction between DCs
and T cells29 or NK cells30-32 is necessary for regulating the effector
cells. All the players, which include DC,14 NK cells,16 and T cells
(this study), express receptors for S1P. It is plausible that S1P may
play a role in bringing these cells together. In the case ofTcells and
mature DC cells, the presence of S1P results in inhibition of T-cell
proliferation. On the other hand, incubating T cells in SFM results
in higher T-cell activation, an activity that is reduced by the
additionofS1P,suggestingthatS1Pisanimportantimmunoregula-
tory molecule present in the serum. Our results may complement
recent results showing that there is lymphopenia due to impairment
of T-cell trafﬁcking occurring in animals treated with S1P or with
drugs that resemble its action.15 Here, we showed that in addition to
inhibitingT-cellcirculation,S1PinhibitspolyclonalT-cellprolifera-
tion, resulting in lower number of these cells.
In summary, our results show for the ﬁrst time that S1P, which is
abundant in human serum and plasma, is an inhibitory molecule for
polyclonal T-cell proliferation, which may represent an important
mechanism for maintaining the homeostasis of the immune system
after encountering foreign particles. Finally, it should be mentioned
that S1P is not only present in serum but is also secreted by
inﬂammatory cells.33 Consequently, it may regulate T-cell activa-
tion inside tissues and during inﬂammation. This, in addition to
negatively regulating liver ﬁbrogenesis,13 makes S1P a very
important natural regulator of immune and nonimmune cells, and
may function similarly to other immunoregulatory molecules such
as transforming growth factor  (TGF-). Unlike TGF-, S1P is
highly abundant in blood and in inﬂammatory tissues and is
difﬁcult to sequester or clear from these sites. Our method of
detecting S1P receptors by ﬂow cytometric analysis should facili-
tate the generation of additional knowledge regarding this impor-
tant immunoregulatory molecule.
References
1. Pyne S, Pyne NJ. Sphingosine 1-phosphate sig-
nalling in mammalian cells. Biochem J. 2000;349:
385-402.
2. Hla T, Lee M-J,Ancellin N, Paik JH, Kluk MJ. Ly-
sophospholipids-receptor revelations. Science.
2001;294:1875-1878.
3. OliveraA, Spiegel S. Sphingosine kinase: a me-
diator of vital cellular functions. Prostaglandins
Other Lipid Mediat. 2001;64:123-134.
4. Ancellin N, Hla T. Differential pharmacological
properties and signal transduction of the sphin-
gosine 1-phosphate receptors EDG-1, EDG-3,
and EDG-5. J Biol Chem. 1999;274:18997-
19002.
5. Windh RT, Lee M-J, Hla T,An S, BarrAJ, Man-
ning DR. Differential coupling of the sphingosine
1-phosphate receptors Edg-1, Edg-3, and H218/
4914 JIN et al BLOOD, 15 JUNE 2003 VOLUME 101, NUMBER 12Edg-5 to the Gi,G q, and G12 families of heterotri-
meric G proteins. J Biol Chem. 1999;274:27351-
27358.
6. Malek RL, Toman RE, Edsall LC, et al. Nrg-1 be-
longs to the endothelial differentiation gene family
of G protein-coupled sphingosine-1-phosphate
receptors. J Biol Chem. 2001;276:5692-5699.
7. Murata N, Sato K, Kon J, et al. Interaction of
sphingosine 1-phosphate with plasma compo-
nents, including lipoproteins, regulates the lipid
receptor-mediated actions. Biochem J. 2000;352:
809-815.
8. Yang L, Yatomi Y, Miura Y, Satoh K, Ozaki Y. Me-
tabolism and functional effects of sphingolipids in
blood cells. Br J Haematol. 1999;107:282-293.
9. Goetzl EJ, Kong Y, Mei B. Lysophosphatidic acid
and sphingosine 1-phosphate protection of T cells
from apoptosis in association with suppression of
Bax. J Immunol. 1999;162:2049-2056.
10. Goetzl EJ, Kong Y, Voice JK. Differential constitu-
tive expression of functional receptors for lyso-
phosphatidic acid by human blood lymphocytes.
J Immunol. 2000;164:4996-4999.
11. Tigyi G, Dyer DL, Miledi R. Lysophosphatidic acid
possesses dual action in cell proliferation. Proc
NatlAcad Sci U SA. 1994;91:1908-1912.
12. Zhang H, Desai NN, OliveraA, Seki T, Brooker G,
Spiegel S. Sphingosine-1-phosphate, a novel
lipid, involved in cellular proliferation. J Cell Biol.
1991;114:155-167.
13. Davaille J, Gallois C, HabibA, et al.Antiprolifera-
tive properties of sphingosine 1-phosphate in hu-
man hepatic myoﬁbroblasts. J Biol Chem. 2000;
275:34628-34633.
14. Idzko M, Panther E, Corinti S. Sphingosine
1-phosphate induces chemotaxis of immature
dendritic cells and modulates cytokine-release in
mature human dendritic cells for emergence of
Th2 immune responses. FASEB J. 2002;16:625-
627.
15. Mandala S, Hajdu R, Bergstrom J, et al.Alteration
of lymphocyte trafﬁcking by sphingosine-1-phos-
phate receptor agonists. Science. 2002;296:346-
349.
16. Kveberg L, Bryceson Y, Inngjerdingen M, Rolstad
B, MaghazachiAA. Sphingosine 1 phosphate in-
duces the chemotaxis of human natural killer
cells: role for heterotrimeric G proteins and phos-
phoinositide 3 kinases. Eur J Immunol. 2002;32:
1856-1864.
17. Al-AoukatyA, GiaidA, Sinoff C, HoAD, Maghaza-
chiAA. Priming effects of granulocyte-macro-
phage colony-stimulating factor are coupled to
cholera toxin-sensitive guanine nucleotide bind-
ing protein in human T lymphocytes. Blood. 1994;
83:1299-1309.
18. Graler MH, Bernhardt G, Lipp M. EDG6, a novel
G-protein-coupled receptor related to receptors
for bioactive lysophospholipids, is speciﬁcally ex-
pressed in lymphoid tissue. Genomics. 1998;53:
164-169.
19. Van Brocklyn JR, Graler MH, Bernhardt G, Hob-
son JP, Lipp M, Spiegel S. Sphingosine-1-phos-
phate is a ligand for the G protein-coupled recep-
tor EDG-6. Blood. 2000;95:2624-2629.
20. Yanai N, Matsui N, Furusawa T, Okubo T, Obinata
M. Sphingosine-1-phosphate and lysophospha-
tidic acid trigger invasion of primitive hematopoi-
etic cells into stromal cell layers. Blood. 2000;96:
139-144.
21. Tolan D, ConwayA-M, Steele L, Pyne S, Pyne
NJ. The identiﬁcation of DL-threo dihydrosphin-
gosine and sphingosine as novel inhibitors of ex-
tracellular signal-regulated kinase signalling in
airway smooth muscle. Br J Pharmacol. 1996;
119:185-186.
22. Spiegel S, Milstien S. Sphingosine 1-phosphate,
a key cell signaling molecule. J Biol Chem. 2002;
277:25851-25854.
23. Yatomi Y, Ohmori T, Rile G, et al. Sphingosine
1-phosphate as a major bioactive lysophospho-
lipid that is released from platelets and interacts
with endothelial cells. Blood. 2000;96:3431-3438.
24. Van Koppen CJ, Meyer zu Heringdorf D, Laser
KT, et al.Activation of a high afﬁnity Gi protein-
coupled plasma membrane receptor by sphin-
gosine-1-phosphate. J Biol Chem. 1996;271;
2082-2087.
25. Meyer zu Heringdorf D, Lass H,Alemany R, et al.
Sphingosine kinase-mediated Ca2 signalling by
G-protein-coupled receptors. EMBO J. 1998;17:
2830-2837.
26. Van Brocklyn JR, Lee M-J, Menzeleev R, et al.
Dual actions of sphingosine-1-phosphate: extra-
cellular through the Gi-coupled receptor Edg-1
and intracellular to regulate proliferation and sur-
vival. J Cell Biol. 1998;142:229-240.
27. Seufferlein T, Withers DJ, Mann D, Rozengurt E.
Dissociation of mitogen-activated protein kinase
activation from p125 focal adhesion kinase ty-
rosine phosphorylation in Swiss 3T3 cells stimu-
lated by bombesin, lysophosphatidic acid, and
platelet-derived growth factor. Mol Biol Cell. 1996;
7:1865-1875.
28. Zheng Y, Voice JK, Kong Y, Goetzl EJ.Altered
expression and functional proﬁle of lysophospha-
tidic acid receptors in mitogen-activated human
blood T lymphocytes. FASEB J. 2000;14:2387-
2389.
29. LangenkampA, Casorati G, Garavaglia C, Della-
bona P, LanzavecchiaA, Sallusto F. T cell priming
by dendritic cells: thresholds for proliferation, dif-
ferentiation and death and intraclonal functional
diversiﬁcation. Eur J Immunol. 2002;32:2046-
2054.
30. Ferlazzo G, Tsang ML, Moretta L, Melioli G,
Steinman RM, Munz C. Human dendritic cells
activate resting natural killer (NK) cells and are
recognized via the NKp30 receptor by activated
NK cells. J Exp Med. 2002;195:343-351.
31. Gerosa F, Baldani-Guerra B, Nisii C, Marchesini
V, Carra G, Trinchieri G. Reciprocal activating
interaction between natural killer cells and den-
dritic cells. J Exp Med. 2002;195:327-333.
32. Piccioli D, Sbrana S, Melandri E, Valiante NM.
Contact-dependent stimulation and inhibition of
dendritic cells by natural killer cells. J Exp Med.
2002;195:335-341.
33. Prieschl EE, Csonga R, Novotny V, Kikuchi GE,
Baumruker T. The balance between sphingosine
and sphingosine 1-phosphate is decisive for mast
cell activation after Fc receptor I triggering.
J Exp Med. 1999;190:1-8.
T CELLS EXPRESS S1P RECEPTORS 4915 BLOOD, 15 JUNE 2003 VOLUME 101, NUMBER 12